NR1H4 and type 2 diabetes mellitus: In T2DM individuals, metformin decreases the abundance and BSH activity of Bacteroides fragilis to increase intestinal levels of glycoursodeoxycholic acid (GUDCA), which has been identified as a novel endogenous FXR antagonist in the gut.